Semaglutide side effects and safety
The molecule that changes appetite also meets a stomach, an eye history and a body with its own vulnerabilities.
Stomach and bowel effects
Semaglutide's gastrointestinal effects have a recognizable pattern. In the pooled STEP analysis, nausea, vomiting, diarrhea and constipation were generally mild to moderate and transient, with events concentrated around dose escalation. The dedicated safety review described nausea in roughly one-third of patients.
Slower stomach emptying helps explain why fullness and discomfort can arrive in the same account. The ease with which mild becomes dismissible irritates me. Severity categories organize trial data; they do not erase the inconvenience or distress of feeling sick.
The post-marketing adverse-event reporting analysis was also dominated by gastrointestinal events. Spontaneous reports extend surveillance into everyday use, with the familiar problem that a report alone cannot establish its cause or a dependable incidence rate.
Community accounts
People describe food taking up less mental space, earlier fullness, weaker cravings and smaller meals. Others mention lower blood-sugar readings or less interest in alcohol. These are anecdotal accounts and not clinical evidence. They suggest experiences worth investigating, with no control group to separate the medicine's effects from everything else changing in a life.
The unpleasant descriptions are often more specific than a trial category: egg-smelling burps, bloating, reflux, constipation alternating with diarrhea, tiredness, altered tastes and aversion to once-appealing foods. Headaches, dizziness and redness or itching at an injection site also appear. No amount or dosing timetable can be inferred from these reports.
The boundary between a quieter appetite and a loss of interest in eating raises a question I cannot dismiss. That boundary sounds important in the accounts, yet their vivid descriptions cannot tell how commonly it is crossed. The possibility that weight reduction includes lean tissue gives the question more substance than a list of pleasing appetite changes.
Thyroid and pancreatic cautions
The thyroid boxed warning derives from C-cell tumors in rodents at supratherapeutic exposures. The human data reviewed did not establish a clear increase in thyroid cancer attributable to semaglutide. A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2, remains a contraindication.
That combination deserves its full wording: an animal finding, an unresolved human signal and a specific label restriction. Both a casual reassurance that removes the warning and a cancer claim that treats the rodent result as a demonstrated human effect leave me unconvinced.
Acute pancreatitis is a class warning. The semaglutide safety review explains why low event counts leave pancreatic-cancer signals unresolved. Severe, sudden abdominal pain calls for urgent medical assessment. A study summary cannot establish the cause of that symptom.
Gallbladder disease and diabetic eye complications
The safety review found increased biliary disease, including gallstones. Rapid and substantial weight loss is thought to account for much of the increase. The risk remains clinically relevant even when the explanation concerns the weight change rather than direct chemical injury.
In SUSTAIN-6, diabetic-retinopathy complications were higher with semaglutide: HR 1.76, 95% CI 1.11–2.78. The signal was concentrated among people with pre-existing retinopathy and rapid glycemic correction. Early worsening from a fast fall in blood glucose is the leading interpretation.
This is an uncomfortable companion to the same trial's cardiovascular benefit. It also reinforces my recurring concern: the speed and character of a bodily change can matter as much as its direction. An existing eye history changes the clinical discussion.
Semaglutide hair loss
An alopecia reporting signal and a separate retrospective study of shedding after weight loss make rapid-weight-loss-associated telogen effluvium a plausible explanation for some reports. They leave direct causation by semaglutide unsettled.
The STEP body-composition substudy found loss of lean mass as well as fat. That is a measured tissue finding, while the degree of subsequent weakness is a separate question. Older adults have particular reason for a clinician to consider muscle preservation. The composition essay examines those distinctions in detail.
Pregnancy and medication review
Semaglutide is contraindicated in pregnancy. Its approximately one-week half-life and persistence for roughly five weeks after the final dose help explain why label guidance calls for stopping well before planned conception, commonly about two months. That is label context for discussion with the prescriber, not an individualized timetable supplied here.
A systematic review of interactions with oral medicines found that delayed gastric emptying generally did not cause clinically significant interactions. It advised particular caution for medicines with a narrow therapeutic range, where a small change in exposure can matter. A reassuring overall pattern can coexist with a specific medicine that needs monitoring.